https://socictopen.socict.org/files/original/14ee6d905348d4e1388fbbab2b83b281.pdf 1dae4f2e0ad5671be20748420eff2186 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Creator An entity primarily responsible for making the resource Federico Angriman, Bruno L Ferreyro, Lisa Burry, Eddy Fan, Niall D Ferguson, Shahid Husain, Shaf H Keshavjee, Enrico Lupia, Laveena Munshi, Samuele Renzi, Onion Gerald V Ubaldo, Bram Rochwerg, Lorenzo Del Sorbo Description An account of the resource The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 signalling in patients with the disease. The efficacy and safety of tocilizumab and sarilumab, which block the binding of IL-6 to its receptor, have been tested in adults with COVID-19-related acute respiratory illness in randomised trials, with important differences in trial design, characteristics of included patients, use of co-interventions, and outcome measurement scales. In this Series paper, we review the clinical and methodological heterogeneity of studies of IL-6 receptor antagonists, and consider how this heterogeneity might have influenced reported treatment effects. Timing from clinical presentation to treatment, severity of illness, and concomitant use of corticosteroids are among the factors that might have contributed to apparently inconsistent results. With an understanding of the sources of variability in these trials, available evidence could be applied to guide clinical decision making and to inform the enrichment of future studies. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Identifier An unambiguous reference to the resource within a given context 10.1016/S2213-2600(21)00139-9 Source A related resource from which the described resource is derived The Lancet. Respiratory medicine